Screening method of tumor immunotherapy prognosis marker and application

A prognostic marker, immunotherapy technology, applied in the field of medical diagnostics, can solve the problems of tumor heterogeneity, non-uniform standards, low throughput, etc., and achieve a good therapeutic effect.

Pending Publication Date: 2020-10-30
SHANGHAI ORIGIMED CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the application process, it is only necessary to detect whether a limited number of specific genes are mutated to predict the efficacy of immunotherapy, which can well solve the problems of low throughput or cost caused by widely used biomarkers such as PD-L1 and TMB. Advanced problems, and the existing biomarkers still have problems such as inconsistent standards and tumor heterogeneity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Screening method of tumor immunotherapy prognosis marker and application
  • Screening method of tumor immunotherapy prognosis marker and application
  • Screening method of tumor immunotherapy prognosis marker and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0091] In a representative embodiment, the method provided by the invention involves 6 steps,

[0092] 1. Through the Fisher test, find the gene mutations related to the expression of 8 immune genes.

[0093] 2. Sorting according to the degree of association between the mutated gene and the expression of the 8 immune genes (that is, sorting according to the OR value of the mutated gene, the higher the OR, the greater the probability of the gene mutation occurring when the gene is highly expressed)

[0094] 3. According to whether the first N genes are mutated, they are divided into mutation group and non-mutation group, and log-rank test is performed to analyze the difference in survival period.

[0095] 4. Among the top M genes, the difference in survival time is the most significant (ie log-rank test, p-value is the smallest). For further dimensionality reduction, the M genes can be clustered into n clusters.

[0096] 5. Carry out correlation analysis in each category (clu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a screening method of a tumor immunotherapy prognosis marker. The screening method comprises the following steps: acquiring expression data, mutation data and clinical curative effect data of a candidate gene group of cancer species to be analyzed; performing statistical independence test on the mutation condition of the candidate gene group and the expression condition ofan immune genome, finding out gene mutation related to the immune genome, and sorting genes in the candidate gene group according to association degrees from high to low, wherein the immune genome comprises CD8A, GZMA, GZMB, IFN [gamma], EOMES, CXCL9, CXCL10, and TBX21; dividing the first N genes into a mutation group and a non-mutation group according to whether the first N genes are mutated ornot, performing survival analysis, and selecting M genes with most significant differences for reservation according to log-rank changes; validating the resulting genes in independent datasets to determine mutation and prognostic correlation thereof.

Description

[0001] related application [0002] This application claims the priority of the Chinese patent application filed on April 07, 2020 with application number 202010265655.7 and titled "Screening method and application of tumor immunotherapy prognostic markers", which is hereby incorporated by reference in its entirety. technical field [0003] The invention relates to the field of medical diagnostics, in particular to a screening method and application of prognostic markers for tumor immunotherapy. Background technique [0004] In recent years, tumor immunotherapy, especially immune checkpoint inhibitors, has brought long-term survival benefits to patients with various tumors. Currently, PD-L1 (programmed death-ligand 1, programmed cell death ligand 1) is the most widely used A wide range of immunotherapy biomarkers, the overexpression of tumor cell PD-L1 can inhibit the function of T cells and make tumor cells immune escape. Multiple clinical trials and multiple analysis indi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G16B20/50G16B20/30G16B35/20
CPCG16B20/50G16B20/30G16B35/20
Inventor 赵松辉宋越强王凯
Owner SHANGHAI ORIGIMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap